Risk of liver injury after α-glucosidase inhibitor therapy in advanced chronic kidney disease patients

Chih Chin Kao, Pei Chen Wu, Che Hsiung Wu, Li Kwang Chen, Hsi Hsien Chen, Mai Szu Wu, Vin Cent Wu

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Although α-glucosidase inhibitors (AGIs) are commonly used for controlling postprandial blood glucose, AGIs-induced liver injuries have been reported. However, the relationship between AGIs and liver injuries in advanced chronic kidney disease (CKD) patients remains unexplored. In this nationwide case-control study, we recruited 1765 advanced diabetic CKD patients, who received AGIs therapy from January 1, 2000 to December 31, 2010 as the study sample and 5295 matched controls. Recent and former AGIs users were defined as patients who received the AGIs prescription for 30-60 d and 30-210 d before the event of liver injury. The risk of AGIs-induced liver injury was examined using time-dependent Cox proportional hazards model. Liver injury occurred in 3.9% of patients in the study group and 3.3% of patients in the control group. AGIs use did not increase the risk of liver injury in advanced CKD patients (P=0.19). The stratified analysis indicated no increased risk of liver injury in all AGIs-using subgroups (all P>0.05). The available evidence supports extending the use of AGIs without increasing the risk of liver injury in patients with advanced CKD. Additional randomized controlled trials are warranted to confirm our results.

Original languageEnglish
Article number18996
JournalScientific Reports
Volume6
DOIs
Publication statusPublished - Jan 11 2016

Fingerprint

Glucosidases
Chronic Renal Insufficiency
Liver
Wounds and Injuries
Therapeutics
Diabetic Nephropathies
Proportional Hazards Models
Prescriptions
Blood Glucose
Case-Control Studies
Randomized Controlled Trials

ASJC Scopus subject areas

  • General

Cite this

Risk of liver injury after α-glucosidase inhibitor therapy in advanced chronic kidney disease patients. / Kao, Chih Chin; Wu, Pei Chen; Wu, Che Hsiung; Chen, Li Kwang; Chen, Hsi Hsien; Wu, Mai Szu; Wu, Vin Cent.

In: Scientific Reports, Vol. 6, 18996, 11.01.2016.

Research output: Contribution to journalArticle

@article{efdc41b3b321435fa1e8d5a4d1c5664b,
title = "Risk of liver injury after α-glucosidase inhibitor therapy in advanced chronic kidney disease patients",
abstract = "Although α-glucosidase inhibitors (AGIs) are commonly used for controlling postprandial blood glucose, AGIs-induced liver injuries have been reported. However, the relationship between AGIs and liver injuries in advanced chronic kidney disease (CKD) patients remains unexplored. In this nationwide case-control study, we recruited 1765 advanced diabetic CKD patients, who received AGIs therapy from January 1, 2000 to December 31, 2010 as the study sample and 5295 matched controls. Recent and former AGIs users were defined as patients who received the AGIs prescription for 30-60 d and 30-210 d before the event of liver injury. The risk of AGIs-induced liver injury was examined using time-dependent Cox proportional hazards model. Liver injury occurred in 3.9{\%} of patients in the study group and 3.3{\%} of patients in the control group. AGIs use did not increase the risk of liver injury in advanced CKD patients (P=0.19). The stratified analysis indicated no increased risk of liver injury in all AGIs-using subgroups (all P>0.05). The available evidence supports extending the use of AGIs without increasing the risk of liver injury in patients with advanced CKD. Additional randomized controlled trials are warranted to confirm our results.",
author = "Kao, {Chih Chin} and Wu, {Pei Chen} and Wu, {Che Hsiung} and Chen, {Li Kwang} and Chen, {Hsi Hsien} and Wu, {Mai Szu} and Wu, {Vin Cent}",
year = "2016",
month = "1",
day = "11",
doi = "10.1038/srep18996",
language = "English",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Risk of liver injury after α-glucosidase inhibitor therapy in advanced chronic kidney disease patients

AU - Kao, Chih Chin

AU - Wu, Pei Chen

AU - Wu, Che Hsiung

AU - Chen, Li Kwang

AU - Chen, Hsi Hsien

AU - Wu, Mai Szu

AU - Wu, Vin Cent

PY - 2016/1/11

Y1 - 2016/1/11

N2 - Although α-glucosidase inhibitors (AGIs) are commonly used for controlling postprandial blood glucose, AGIs-induced liver injuries have been reported. However, the relationship between AGIs and liver injuries in advanced chronic kidney disease (CKD) patients remains unexplored. In this nationwide case-control study, we recruited 1765 advanced diabetic CKD patients, who received AGIs therapy from January 1, 2000 to December 31, 2010 as the study sample and 5295 matched controls. Recent and former AGIs users were defined as patients who received the AGIs prescription for 30-60 d and 30-210 d before the event of liver injury. The risk of AGIs-induced liver injury was examined using time-dependent Cox proportional hazards model. Liver injury occurred in 3.9% of patients in the study group and 3.3% of patients in the control group. AGIs use did not increase the risk of liver injury in advanced CKD patients (P=0.19). The stratified analysis indicated no increased risk of liver injury in all AGIs-using subgroups (all P>0.05). The available evidence supports extending the use of AGIs without increasing the risk of liver injury in patients with advanced CKD. Additional randomized controlled trials are warranted to confirm our results.

AB - Although α-glucosidase inhibitors (AGIs) are commonly used for controlling postprandial blood glucose, AGIs-induced liver injuries have been reported. However, the relationship between AGIs and liver injuries in advanced chronic kidney disease (CKD) patients remains unexplored. In this nationwide case-control study, we recruited 1765 advanced diabetic CKD patients, who received AGIs therapy from January 1, 2000 to December 31, 2010 as the study sample and 5295 matched controls. Recent and former AGIs users were defined as patients who received the AGIs prescription for 30-60 d and 30-210 d before the event of liver injury. The risk of AGIs-induced liver injury was examined using time-dependent Cox proportional hazards model. Liver injury occurred in 3.9% of patients in the study group and 3.3% of patients in the control group. AGIs use did not increase the risk of liver injury in advanced CKD patients (P=0.19). The stratified analysis indicated no increased risk of liver injury in all AGIs-using subgroups (all P>0.05). The available evidence supports extending the use of AGIs without increasing the risk of liver injury in patients with advanced CKD. Additional randomized controlled trials are warranted to confirm our results.

UR - http://www.scopus.com/inward/record.url?scp=84954181723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954181723&partnerID=8YFLogxK

U2 - 10.1038/srep18996

DO - 10.1038/srep18996

M3 - Article

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 18996

ER -